This activity is supported by an educational grant from Celgene and Takeda Oncology.

New Drugs and Novel Mechanisms of Action in Treating Patients with Multiple Myeloma

Jonathan Kaufman, MD
The Winship Cancer Institute of Emory University

Charise Gleason, MSN, NP-BC, AOCNP®
The Winship Cancer Institute of Emory University

Despite the fact that multiple myeloma remains incurable, mean overall survival has improved dramatically as newer game-changing therapies enter the scene. At the same time, treatment decisions are becoming more complex. This educational activity provides indispensable information regarding risk categories, mechanisms of action for newer drugs, appropriate therapeutic options and sequencing, including identification of transplant eligible patients, and the management of toxicities related to newer drug regimens, thus equipping advanced practitioners to provide optimum clinical support for their patients throughout the trajectory of their disease. 


Download Podcast


Download Transcript


Download Slides


Download Slides & Transcripts


These CME/CE/CPE accredited activities are jointly provided by

JADPRO CE Logo Harborside Press Logo APSHO Logo Annenberg Logo
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.